|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Abbott (NYSE: ABT), a global health care company that develops pharmaceuticals and medical products, including nutritionals, devices and diagnostics. |
|---|---|
| Transferring Party | Kos Pharmaceuticals, Inc. (Nasdaq:KOSP), a developer of proprietary prescription products for the treatment of chronic diseases with a focus on the cardiovascular, metabolic and respiratory disease area. |
| Sector | Biopharmaceuticals |
| Date | December 14, 2006 |
| Analysis Expands Abbott's presence in lipid management market and strengthens its late-stage pipeline. The lipid management market is the single largest pharmaceutical segment and continues to grow at double-digit rates. Deal value -- $3.7b. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |